scispace - formally typeset
Search or ask a question
Topic

Management of heart failure

About: Management of heart failure is a research topic. Over the lifetime, 1204 publications have been published within this topic receiving 42767 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: Authors/Task Force Members: Piotr Ponikowski* (Chairperson) (Poland), Adriaan A. Voors* (Co-Chair person) (The Netherlands), Stefan D. Anker (Germany), Héctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK)

13,400 citations

Journal ArticleDOI
TL;DR: In patients with heart failure and a preserved ejection fraction, treatment with spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure.
Abstract: Background Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction. We evaluated the effects of spironolactone in patients with heart failure and a preserved left ventricular ejection fraction. Methods In this randomized, double-blind trial, we assigned 3445 patients with symptomatic heart failure and a left ventricular ejection fraction of 45% or more to receive either spironolactone (15 to 45 mg daily) or placebo. The primary outcome was a composite of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure. Results With a mean follow-up of 3.3 years, the primary outcome occurred in 320 of 1722 patients in the spironolactone group (18.6%) and 351 of 1723 patients in the placebo group (20.4%) (hazard ratio, 0.89; 95% confidence interval [CI], 0.77 to 1.04; P = 0.14). Of the components of the primary outcome, only hospitalization for heart failure had a significantly lower incidence in the spironolactone group than in the placebo group (206 patients [12.0%] vs. 245 patients [14.2%]; hazard ratio, 0.83; 95% CI, 0.69 to 0.99, P = 0.04). Neither total deaths nor hospitalizations for any reason were significantly reduced by spironolactone. Treatment with spiron olactone was associated with increased serum creatinine levels and a doubling of the rate of hyperkalemia (18.7%, vs. 9.1% in the placebo group) but reduced hypokalemia. With frequent monitoring, there were no significant differences in the incidence of serious adverse events, a serum creatinine level of 3.0 mg per deciliter (265 μmol per liter) or higher, or dialysis. Conclusions In patients with heart failure and a preserved ejection fraction, treatment with spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure. (Funded by the National Heart, Lung, and Blood Institute; TOPCAT ClinicalTrials.gov number, NCT00094302.)

1,930 citations

Journal ArticleDOI
TL;DR: In the current ESC guidelines for the management of heart failure, B-type natriuretic peptides are integrated for the first time into a concrete diagnostic algorithm for patients with suspected first presentation of chronic heart failure.
Abstract: In the current ESC guidelines for the management of heart failure,1 Dickstein et al. for the first time integrate B-type natriuretic peptides into a concrete diagnostic algorithm for patients with suspected first presentation of chronic heart failure. Patient presentation in this case most probably happens in primary care. Therefore, it seems uncommon that natriuretic peptides are …

1,927 citations

Journal ArticleDOI
TL;DR: Biykem Bozkurt, MD, PHD, FACC, FAHA*y Javed Butler,MD, MBA, MPH, F ACC,FAHA*z Donald E. Casey, JR, MD; Monica M.Casey, JR; and Cheryl Westlake,PHD, RN, ACNS-BC, FAha, FHFSA.

1,468 citations

Journal ArticleDOI
TL;DR: In this trial, prophylactic ICD implantation in patients with symptomatic systolic heart failure not caused by coronary artery disease was not associated with a significantly lower long-term rate of death from any cause than was usual clinical care.
Abstract: BackgroundThe benefit of an implantable cardioverter–defibrillator (ICD) in patients with symptomatic systolic heart failure caused by coronary artery disease has been well documented. However, the evidence for a benefit of prophylactic ICDs in patients with systolic heart failure that is not due to coronary artery disease has been based primarily on subgroup analyses. The management of heart failure has improved since the landmark ICD trials, and many patients now receive cardiac resynchronization therapy (CRT). MethodsIn a randomized, controlled trial, 556 patients with symptomatic systolic heart failure (left ventricular ejection fraction, ≤35%) not caused by coronary artery disease were assigned to receive an ICD, and 560 patients were assigned to receive usual clinical care (control group). In both groups, 58% of the patients received CRT. The primary outcome of the trial was death from any cause. The secondary outcomes were sudden cardiac death and cardiovascular death. ResultsAfter a median follow-...

1,239 citations


Network Information
Related Topics (5)
Heart failure
107.8K papers, 3.5M citations
92% related
Atrial fibrillation
50.2K papers, 1.3M citations
90% related
Ejection fraction
47.6K papers, 1.6M citations
89% related
Myocardial infarction
119K papers, 4.2M citations
89% related
Coronary artery disease
77.6K papers, 2.2M citations
88% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
202315
202214
202147
202058
201949
201856